Role of gemifloxacin in community-acquired pneumonia

摘要: Community-acquired pneumonia (CAP) is the leading cause of death due to bacterial infection. It accounts for 10 million physician office visits in USA annually. However, 80% these are managed community, usually with oral antibiotic therapy. Typically, such courses have lasted days or longer. Streptococcus pneumoniae 25% all CAP infections; resistance among S. classes antibiotics, including fluoroquinolones, poses new and shifting challenges primary care physician. Gemifloxacin a potent agent, active against pneumococci atypical pathogens. Administered once daily 5 days, gemifloxacin highly efficacious well tolerated. administered 5–7 cost effective safe alternative both parenteral antimicrobials, which may not cover emerging resistant respiratory